Literature DB >> 12721505

Somatostatin and somatostatin receptor physiology.

Philip Barnett1.   

Abstract

Since the discovery of somatostatin (SST) over three decades ago, its ubiquitous distribution and manifold functions are still being documented. SST is synthesized in the hypothalamus and transported to the anterior pituitary gland where it tonicaly inhibits GH and TSH secretion as well as being responsible for GH pulsatile release. Several internal feedback loops, sleep, exercise, and chemical agents control and influence SST release. SST also impacts the function of a wide variety of cells and organ systems throughout the body. Knowledge of the structures of the SSTs has resulted in recognition of the essential four core conserved residues responsible for their actions. The SSTs act through six separate SST cell surface receptors (SSTRs), members of the family of G protein-coupled receptors. Receptor ligand binding (SST/SSTR) results in cellular activities specific for each receptor, or receptor combinations, and their tissue/cell localization. Understanding the structure/function relationship of the SSTs and their receptors, including the internalization of SST/SSTR complexes, has facilitated the development of a variety of novel pharmacologic agents for the diagnosis and treatment of neuroendocrine tumors and unfolding new applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721505     DOI: 10.1385/ENDO:20:3:255

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  185 in total

Review 1.  Peptides in the brain: the new endocrinology of the neuron.

Authors:  R Guillemin
Journal:  Science       Date:  1978-10-27       Impact factor: 47.728

2.  Effects of rat growth hormone (rGH)-releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitary cells.

Authors:  J Fukata; D J Diamond; J B Martin
Journal:  Endocrinology       Date:  1985-08       Impact factor: 4.736

3.  Differential control of insulin secretion and somatostatin-receptor recruitment in isolated pancreatic islets.

Authors:  K E Sussman; H B Pollard; J W Leitner; R Nesher; J Adler; E Cerasi
Journal:  Biochem J       Date:  1983-07-15       Impact factor: 3.857

4.  On the actions of the growth hormone-releasing hexapeptide, GHRP.

Authors:  C Y Bowers; A O Sartor; G A Reynolds; T M Badger
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

5.  Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Authors:  I Shimon; X Yan; J E Taylor; M H Weiss; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

6.  Defective hypothalamic growth hormone (GH)-releasing hormone activity may contribute to declining GH secretion with age in man.

Authors:  E C degli Uberti; M R Ambrosio; S G Cella; A R Margutti; G Trasforini; A E Rigamonti; E Petrone; E E Müller
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

7.  Mutational analysis of the mouse somatostatin receptor type 5 gene promoter.

Authors:  Whitney W Woodmansee; Rhonda L Mouser; David F Gordon; Janet M Dowding; William M Wood; E Chester Ridgway
Journal:  Endocrinology       Date:  2002-06       Impact factor: 4.736

8.  In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue.

Authors:  J C Reubi; B Waser; U Horisberger; E Krenning; S W Lamberts; J O Gebbers; P Gersbach; J A Laissue
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

9.  Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep.

Authors:  V Guillaume; E Magnan; M Cataldi; A Dutour; N Sauze; M Renard; H Razafindraibe; B Conte-Devolx; R Deghenghi; V Lenaerts
Journal:  Endocrinology       Date:  1994-09       Impact factor: 4.736

10.  Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.

Authors:  C A Jaffe; P J Ho; R Demott-Friberg; C Y Bowers; A L Barkan
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

View more
  38 in total

Review 1.  G-Protein-Coupled Receptor Signaling in Cilia.

Authors:  Kirk Mykytyn; Candice Askwith
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-09-01       Impact factor: 10.005

Review 2.  The metabolic effects of growth hormone in adipose tissue.

Authors:  Valéria Ernestânia Chaves; Fernando Mesquita Júnior; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

3.  Clinical Utility of 68Ga-DOTANOC Positron Emission Tomography-Computed Tomography Scan on Postoperative Assessment of Juvenile Nasal Angiofibroma.

Authors:  Pirabu Sakthivel; Alok Thakar; Arun Prashanth; Sreedharan Thankarajan Arunraj; Rakesh Kumar; Rakesh Kumar
Journal:  Indian J Nucl Med       Date:  2020-10-21

4.  Monitoring endosomal trafficking of the g protein-coupled receptor somatostatin receptor 3.

Authors:  Cristy Tower-Gilchrist; Melanie L Styers; Bradley K Yoder; Nicolas F Berbari; Elizabeth Sztul
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

5.  Endosomal trafficking of the G protein-coupled receptor somatostatin receptor 3.

Authors:  Cristy Tower-Gilchrist; Eunjoo Lee; Elizabeth Sztul
Journal:  Biochem Biophys Res Commun       Date:  2011-09-07       Impact factor: 3.575

Review 6.  Neuronal ciliary signaling in homeostasis and disease.

Authors:  Jill A Green; Kirk Mykytyn
Journal:  Cell Mol Life Sci       Date:  2010-06-11       Impact factor: 9.261

7.  Haplotype analysis of the promoter region of phosphodiesterase type 8B (PDE8B) in correlation with inactivating PDE8B mutation and the serum thyroid-stimulating hormone levels.

Authors:  Anelia Horvath; Fabio Faucz; Gabriela P Finkielstain; Maria Eleni Nikita; Anya Rothenbuhler; Madson Almeida; Veronica Mericq; Constantine A Stratakis
Journal:  Thyroid       Date:  2010-04       Impact factor: 6.568

8.  Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro.

Authors:  Yang Shen; Mulan Ren; Yuehua Shi; Yunxia Zhang; Yunlang Cai
Journal:  Exp Ther Med       Date:  2011-08-11       Impact factor: 2.447

9.  Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy.

Authors:  Marta Bondanelli; Maria Rosaria Ambrosio; Maria Chiara Zatelli; Luigi Cavazzini; Laura Al Jandali Rifa'y; Ettore C degli Uberti
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

10.  Somatostatin and cancer: applying endocrinology to oncology.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2004-08-23       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.